These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3394654)

  • 21. Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits.
    Bräsen JH; Koenig K; Bach H; Kontush A; Heinle H; Witting PK; Ylä-Herttuala S; Stocker R; Beisiegel U
    Atherosclerosis; 2002 Aug; 163(2):249-59. PubMed ID: 12052471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits.
    Fruebis J; Steinberg D; Dresel HA; Carew TE
    J Clin Invest; 1994 Jul; 94(1):392-8. PubMed ID: 8040279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S 12340: a potent inhibitor of the oxidative modification of low-density lipoprotein in vitro and ex vivo in WHHL rabbits.
    Breugnot C; Privat S; Guillonneau C; Regnier G; Bouzom F; Vilaine JP; Lenaers A
    J Pharmacol Exp Ther; 1994 May; 269(2):515-20. PubMed ID: 8182520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques.
    Nagano Y; Nakamura T; Matsuzawa Y; Cho M; Ueda Y; Kita T
    Atherosclerosis; 1992 Feb; 92(2-3):131-40. PubMed ID: 1632845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect?
    Finckh B; Niendorf A; Rath M; Beisiegel U
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S77-80. PubMed ID: 2044649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit.
    Naruszewicz M; Carew TE; Pittman RC; Witztum JL; Steinberg D
    J Lipid Res; 1984 Nov; 25(11):1206-13. PubMed ID: 6520542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy.
    O'Leary VJ; Tilling L; Fleetwood G; Stone D; Darley-Usmar V
    Atherosclerosis; 1996 Jan; 119(2):169-79. PubMed ID: 8808494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anthocyanins increase low-density lipoprotein and plasma cholesterol and do not reduce atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits.
    Finné Nielsen IL; Elbøl Rasmussen S; Mortensen A; Ravn-Haren G; Ma HP; Knuthsen P; Hansen BF; McPhail D; Freese R; Breinholt V; Frandsen H; Dragsted LO
    Mol Nutr Food Res; 2005 Apr; 49(4):301-8. PubMed ID: 15759306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis.
    Ku G; Doherty NS; Wolos JA; Jackson RL
    Am J Cardiol; 1988 Jul; 62(3):77B-81B. PubMed ID: 3260741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Studies on atherosclerosis with an animal model].
    Nagano Y; Kita T
    Nihon Ronen Igakkai Zasshi; 1992 Apr; 29(4):249-52. PubMed ID: 1614001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881.
    Feldman DL; Mogelesky TC; Sharif R; Sawyer WK; Jeune M; Hu CW; Leonards KS; Prescott MF
    Atherosclerosis; 1999 Jun; 144(2):343-55. PubMed ID: 10407495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants.
    Fruebis J; Bird DA; Pattison J; Palinski W
    J Lipid Res; 1997 Dec; 38(12):2455-64. PubMed ID: 9458269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoradiographic analysis of the distribution of 125I-tyramine-cellobiose-LDL in atherosclerotic lesions of the WHHL rabbit.
    Rosenfeld ME; Carew TE; von Hodenberg E; Pittman RC; Ross R; Steinberg D
    Arterioscler Thromb; 1992 Aug; 12(8):985-95. PubMed ID: 1637798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dextran sulfate, a competitive inhibitor for scavenger receptor, prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
    Tsubamoto Y; Yamada N; Watanabe Y; Inaba T; Shiomi M; Shimano H; Gotoda T; Harada K; Shimada M; Ohsuga J
    Atherosclerosis; 1994 Mar; 106(1):43-50. PubMed ID: 8018106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
    Regnström J; Walldius G; Nilsson S; Elinder LS; Johansson J; Mölgaard J; Holme I; Olsson AG; Nilsson J
    Atherosclerosis; 1996 Sep; 125(2):217-29. PubMed ID: 8842353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits.
    Fruebis J; Silvestre M; Shelton D; Napoli C; Palinski W
    J Lipid Res; 1999 Nov; 40(11):1958-66. PubMed ID: 10552999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?
    Sasahara M; Raines EW; Chait A; Carew TE; Steinberg D; Wahl PW; Ross R
    J Clin Invest; 1994 Jul; 94(1):155-64. PubMed ID: 8040256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits.
    Braesen JH; Beisiegel U; Niendorf A
    Virchows Arch; 1995; 426(2):179-88. PubMed ID: 7757289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro.
    Regnström J; Walldius G; Carlson LA; Nilsson J
    Atherosclerosis; 1990 May; 82(1-2):43-51. PubMed ID: 2360919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of low density lipoprotein oxidation by thyronines and probucol.
    Hanna AN; Feller DR; Witiak DT; Newman HA
    Biochem Pharmacol; 1993 Feb; 45(3):753-62. PubMed ID: 8442772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.